Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.255
-0.060 (-2.59%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,564,891
Open
2.330
Bid (Size)
2.220 (20)
Ask (Size)
2.290 (12)
Prev. Close
2.315
Today's Range
2.250 - 2.370
52wk Range
1.990 - 5.775
Shares Outstanding
142,183,418
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Allogene Therapeutics Announces Participation in December Investor Conferences
November 19, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
November 18, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-37.71%
-37.71%
1 Month
-24.83%
-24.83%
3 Month
-12.60%
-12.60%
6 Month
-7.58%
-7.58%
1 Year
-10.52%
-10.52%
More News
Read More
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
November 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
August 08, 2024
Via
Benzinga
Analyst Ratings For Allogene Therapeutics
May 31, 2024
Via
Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
May 15, 2024
Via
Benzinga
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
November 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
November 05, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in November Investor Conferences
November 04, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
October 30, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
October 29, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
October 22, 2024
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
September 30, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
September 26, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
August 08, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Via
InvestorPlace
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
August 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
July 31, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
July 19, 2024
Via
Benzinga
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
July 01, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
June 20, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
May 28, 2024
Via
InvestorPlace
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 23, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
May 21, 2024
Via
Benzinga
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 21, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.